Trump Considering Firing FDA Commissioner Marty Makary
President Trump is considering dismissing Dr. Marty Makary as commissioner of the Food and Drug Administration following frustration with his performance. A source familiar with the matter said no final decision has been reached. NBC News reported the development on May 9, 2026.
Nbc NewsThough a final decision has not been made, the source said the administration has reviewed Makary's leadership at the agency. NBC News reported the information on Saturday. The FDA commissioner oversees regulation of food safety, pharmaceuticals, medical devices and other public health responsibilities.
Any change in leadership would require Senate confirmation of a successor under federal law. His tenure has included decisions on drug approvals and regulatory policy that have drawn internal review. The potential dismissal comes as the agency continues work on multiple fronts, including oversight of ongoing clinical trials and responses to public health inquiries.
No timeline for a decision was provided by the source.
Background on the FDA Role The position of FDA commissioner is a presidential appointment that directs one of the largest regulatory agencies in the federal government. Commissioners serve at the pleasure of the president but typically remain in place unless removed for policy or performance reasons.
Previous changes in FDA leadership have occurred during shifts in administration priorities on issues such as vaccine approvals, tobacco regulation and food labeling standards. Any removal of the current commissioner would follow established federal personnel procedures.
Key Facts
Story Timeline
3 events- May 8, 10:03 PM ET
3 new sources added: The Washington Times, Just the News, Financial Times
3 sourcesThe Washington Times · Just the News · Financial Times - 2026-05-09
NBC News reported President Trump is considering firing FDA Commissioner Marty Makary.
1 sourceNbc News - 2025
Dr. Marty Makary was confirmed as FDA commissioner.
1 sourceNbc News
Potential Impact
- 01
A change in FDA leadership would require Senate confirmation of a new commissioner.
- 02
Agency staff and regulated industries may face temporary uncertainty during any transition period.
- 03
Ongoing regulatory reviews of drugs and devices could experience short-term delays.
Transparency Panel
Related Stories
Fox NewsU.S. Repatriates Americans from Cruise Ship with Hantavirus Cases for Quarantine in Nebraska
Federal officials are preparing a medical repatriation flight for at least 17 Americans aboard the M/V Hondius, which is expected to dock in Spain’s Canary Islands. The ship is at the center of an outbreak that began in early April, with six confirmed infections, two suspected ca…
StatSpain Prepares to Receive Hantavirus-Affected Cruise Ship in Canary Islands
Spanish authorities are preparing to receive more than 140 passengers and crew from the MV Hondius, which is expected to arrive in Tenerife on Sunday. Health officials plan to evacuate passengers to an isolated area while the U.S. and U.K. send planes to repatriate their citizens…
The TimesTrump Nominates Dr. Nicole Saphier as Surgeon General
President Trump announced Dr. Nicole Saphier, a 44-year-old radiologist and Fox News contributor, as his nominee for U.S. surgeon general on Thursday, following the withdrawal of Dr. Casey Means due to insufficient Senate support. Saphier, who authored a book titled Make America…